Edition:
United Kingdom

Solasia Pharma KK (4597.T)

4597.T on Tokyo Stock Exchange

421JPY
22 Nov 2017
Change (% chg)

¥35 (+9.07%)
Prev Close
¥386
Open
¥395
Day's High
¥421
Day's Low
¥380
Volume
16,983,500
Avg. Vol
3,621,689
52-wk High
¥652
52-wk Low
¥219

Chart for

About

Solasia Pharma KK is a Japan-based pharmaceutical company. The Company is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. It focuses on commercializing assets in the oncology/hematology field, by developing products... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): ¥29,134.29
Shares Outstanding(Mil.): 87.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Pledpharma and Solasia enter license agreement on Pledox in Asia

* PLEDPHARMA AND SOLASIA ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE PLEDOX® IN ASIA

20 Nov 2017

BRIEF- Solasia Pharma to sign distributorship agreement with ITOCHU

* Says it plans to sign a distributorship agreement with ITOCHU Corp, regarding sales of the company's products in China (except Hong Kong and Macau )

13 Sep 2017

BRIEF- Solasia Pharma announces approval of episil® oral liquid in Japan

* Says it obtained the marketing approval of episil®(SP-03), in Japan, on July 6

07 Jul 2017

BRIEF- JapanBridge (Ireland) cuts voting power in Solasia Pharma KK to 19.7 pct

* Says JapanBridge (Ireland) Limited cut voting power in the company to 19.7 percent from 24 percent

29 Jun 2017

BRIEF- JapanBridge (Ireland) to cut voting power in Solasia Pharma KK to 7.9 pct

* Says its second biggest shareholder JapanBridge (Ireland) Limited will cut voting power in the company to 7.9 percent from 24 percent

28 Jun 2017

Earnings vs. Estimates